uniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School
December 02 2016 - 7:05AM
Lexington, MA and Amsterdam, the Netherlands, December 2,
2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy,
today announced its participation in two panel discussions at the
2016 Genetic Rx Conference taking place at the Harvard Medical
School, in Boston, MA, on December 8, 2016.
Both Harald Petry, Ph.D. and Christian Meyer,
MD, Ph.D. are among several industry leaders to co-host the
Genetic Rx Conference and each also will participate in the
following panel discussions:
- Key Collaborations with AcademiaParticipating: Harald
Petry, PhD - Chief Scientific Officer Time slot:
Thursday, December 8th, 2:15 p.m. EST
- Engaging Regulators, When and How?Participating:
Christian Meyer, MD, PhD - Chief Medical OfficerTime slot:
Thursday, December 8th, 3.30 p.m. EST
About uniQure uniQure is delivering on
the promise of gene therapy - single treatments with potentially
curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary
and partnered gene therapies to treat patients with
liver/metabolic, central nervous system and cardiovascular
diseases. www.uniQure.com
uniQure Forward-Looking StatementsThis
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as
"anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "look forward to", "may," "plan," "potential," "predict,"
"project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements regarding the
implementation and effects of the Company's new strategic and
organizational changes, the development of our gene therapy product
candidates, the success of our collaborations and the risk of
cessation, delay or lack of success of any of our ongoing or
planned clinical studies and/or development of our product
candidates. Our actual results could differ materially from those
anticipated in these forward-looking statements for many reasons,
including, without limitation, risks associated with corporate
reorganizations and strategic shifts, collaboration arrangements,
our and our collaborators' clinical development activities,
regulatory oversight, product commercialization and intellectual
property claims, as well as the risks, uncertainties and other
factors described under the heading "Risk Factors" in uniQure's
2015 Annual Report on Form 20-F filed with the Securities and
Exchange Commission on April 4, 2016. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
uniQure Contacts:
Maria E. CantorDirect:
339-970-7536Mobile: 617-680-9452m.cantor@uniQure.com Tom
MaloneDirect: 339-970-7558Mobile:
339-223-8541t.malone@uniQure.com
Eva M. MulderDirect: +31 20 240
6103Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/237f71ef-3423-44b4-9365-7ef9102d8bcc
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Aug 2024 to Sep 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Sep 2023 to Sep 2024